The 26 references in paper VA Dobronravov , E. Bogdanova O., N. Semenova YU., O. Beresneva N., M. Parastaeva M., O. Galkina V., I. Zubina M., E. Zueva E., G. Ivanova T., I. Kaukov G., IL. Kovalenko ., L. Kotenko V., G. Nuftullina M., V. Sipovsky G., VA Zinserling , A. Smirnov V., В. Добронравов А., Е. Богданова О., Н. Семенова Ю., О. Береснева Н., М. Парастаева М., О. Галкина В., И. Зубина М., Е. Зуева Е., Г. Иванова Т., И. Каюков Г., Т. Коваленко Л., Л. Котенко В., Г. Нутфуллина М., В. Сиповский Г., В. Цинзерлинг А., А. Смирнов В. (2014) “Почечная экспрессия белка aKlotho, фактор роста фибробластов 23 и паратиреоидный гормон при экспериментальном моделировании ранних стадий хронического повреждения почек // Renal aKlotho expression, fibroblast growth factor 23 and parathyroid hormone in experimental modeling of early stages of chronic kidney injury” / spz:neicon:nefr:y:2014:i:2:p:72-78

1
Kestenbaum В, Sampson JN, Rudser KD. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16(2):520-528
(check this in PDF content)
2
Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и Klotho. Нефрология 2011;15(4):11-20
(check this in PDF content)
3
Craver L, Marco MP, Martнnez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22(4):1171-1176
(check this in PDF content)
4
Hruska KA, Mathew S, Lund R et al. Hyperphosphatemia of Рис. 5. Количественная морфометрия результатов иммуногистохимического исследования экспрессии белка αKlotho в почке (ордината указывает долю тубулоинтерстиция с продуктом ИГХ-реакции на αKlotho): a – p≤0,02 в сравнении с SHR(1); b – p<0,001 в сравнении с 3/4 NE(1); c – p=0,007 в сравнении с 5/6 NE(1); d – p=0,012 в сравнении с SHR(2); e – p<0,001 в сравнении с 3/4 NE(2) (другие межгрупповые различия недостоверны). chronic kidney disease. Kidney Int 2008;74(2):148-157
(check this in PDF content)
5
Hu MC, Kuro-o M, Moe OW. Klotho and chronic kidney disease. Contrib Nephrol 2013;180:47-63
(check this in PDF content)
6
Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007;194(1):1-10
(check this in PDF content)
7
Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975–980
(check this in PDF content)
8
Sakan H, Nakatani K, Asai O et al. Reduced Renal б-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism. PLoS One. 2014;9(1):e86301. doi: 10.1371/journal.pone.0086301
(check this in PDF content)
9
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82(7):737-747
(check this in PDF content)
10
Isakova T, Xie H, Barchi-Chung A et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011;6:2688–9520
(check this in PDF content)
11
Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant 2012;27(7):2650-2657
(check this in PDF content)
12
Takahashi S, Okada K, Nagura Y et al. Three-quarters nephrectomy in rats as a model of early renal failure. Jpn J Nephrol 1991;33(1):27-31
(check this in PDF content)
13
Береснева ОН, Парастаева ММ, Иванова ГТ. и др. Оценка кардиопротективного действия малобелковой соевой диеты и уровень неорганических анионов сыворотки крови у спонтанно-гипертензивных крыс с нефрэктомией. Нефрология 2007;11(3):70-76
(check this in PDF content)
14
Ormrod D, Miller T. Experimental uremia. Description of a model producing varying degrees of stable uremia. Nephron 1980; 26(5):249-254
(check this in PDF content)
15
Feldman HI, Appel LJ, Chertow GM et al. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol 2003;14:148–153
(check this in PDF content)
16
Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16:2205–2215
(check this in PDF content)
17
Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272–2279
(check this in PDF content)
18
Husen M, Fischer AK, Lehnhardt A et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010;78:200–206
(check this in PDF content)
19
Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev
(check this in PDF content)
20
2;92(1):131-155 20. Aizawa H, Saito Y, Nakamura T et al. Downregulation of the Klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998; 249: 865–871
(check this in PDF content)
21
Burnett SM, Gunawardene SC, Bringhurst FR et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006;21:1187–1196
(check this in PDF content)
22
Haruna Y, Kashihara N, Satoh M et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA 2007; 104: 2331–2336
(check this in PDF content)
23
Wang Y, Sun Z. Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009; 54:810–817
(check this in PDF content)
24
Moe SM, Radcliffe JS, White KE et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 2011;26(11):2672-2681
(check this in PDF content)
25
Spichtig D, Zhang H, Mohebbi N et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 2014; doi:10.1038/ ki.2013.526
(check this in PDF content)
26
Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr 2012;22(1):61-86 Авторы заявляют об отсутствии конфликта интересов.
(check this in PDF content)